期刊文献+

艾曲泊帕治疗原发免疫性血小板减少症致严重皮肤变态反应一例并文献复习 被引量:1

Severe cutaneous allergic reaction caused by eltrombopag in treatment of primary immune thrombocytopenia:report of one case and review of literature
原文传递
导出
摘要 目的提高对艾曲泊帕治疗原发免疫性血小板减少症(ITP)发生严重皮肤变态反应的认识。方法回顾性分析湖北医药学院附属人民医院收治的1例艾曲泊帕治疗后发生皮肤严重变态反应的ITP患者临床资料,并结合文献进行复习。结果该例ITP患者因糖皮质激素等治疗无效而给予艾曲泊帕治疗,9 d后出现胸、背部散在红色皮疹,3 d后皮疹蔓延全身,并出现皮肤松解脱落及水泡,经停用艾曲泊帕,给予糖皮质激素和丙种球蛋白冲击治疗、抗过敏及对症支持治疗后皮疹逐渐消退,停用艾曲泊帕后换用重组人促血小板生成素(TPO)升血小板治疗,TPO治疗过程中未发生皮肤变态反应。结论艾曲泊帕所致严重皮肤变态反应临床罕见,应引起临床医师的高度关注,一旦发生应及时停药并换用其他替代产品,给予抗过敏及对症支持治疗可改善症状。
作者 杨华强 覃骏 李红 余帮伟 王黎 聂豪 戢操 Yang Huaqiang;Qin Jun;Li Hong;Yu Bangwei;Wang Li;Nie Hao;Zhe Cao(Department of Hematology,Renmin Hospital,Hubei University of Medicine,Shiyan 442000,China)
出处 《白血病.淋巴瘤》 CAS 2021年第5期309-311,共3页 Journal of Leukemia & Lymphoma
基金 湖北省教育厅基金资助重点项目(D20142104)。
  • 相关文献

参考文献5

二级参考文献35

  • 1ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 2NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 3British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 4WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 5WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 6BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 7BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 8ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.
  • 9SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512.
  • 10KuterDJ, BusselJB, LyonsRM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet,2008,371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2.

共引文献429

同被引文献3

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部